Robert A. Figlin

52.5k total citations · 12 hit papers
470 papers, 38.0k citations indexed

About

Robert A. Figlin is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Robert A. Figlin has authored 470 papers receiving a total of 38.0k indexed citations (citations by other indexed papers that have themselves been cited), including 337 papers in Pulmonary and Respiratory Medicine, 197 papers in Molecular Biology and 177 papers in Oncology. Recurrent topics in Robert A. Figlin's work include Renal cell carcinoma treatment (289 papers), Renal and related cancers (147 papers) and Cancer Genomics and Diagnostics (126 papers). Robert A. Figlin is often cited by papers focused on Renal cell carcinoma treatment (289 papers), Renal and related cancers (147 papers) and Cancer Genomics and Diagnostics (126 papers). Robert A. Figlin collaborates with scholars based in United States, France and Canada. Robert A. Figlin's co-authors include Arie S. Belldegrun, Robert J. Motzer, Thomas E. Hutson, Stéphane Oudard, Allan J. Pantuck, Ronald M. Bukowski, Piotr Tomczak, M. Dror Michaelson, Sindy T. Kim and Sylvie Négrier and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Robert A. Figlin

465 papers receiving 37.1k citations

Hit Papers

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell... 2001 2026 2009 2017 2007 2007 2008 2009 2005 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
    2007 4.5k citations Robert J. Motzer, Thomas E. Hutson et al. profile →
  2. Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
    2007 2.8k citations Gary R. Hudes, Piotr Tomczak et al. profile →
  3. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
    2008 2.3k citations Robert J. Motzer, Stéphane Oudard et al. profile →
  4. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
    2009 1.7k citations Robert J. Motzer, Thomas E. Hutson et al. Journal of Clinical Oncology profile →
  5. Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
    2005 1.3k citations Robert J. Motzer, M. Dror Michaelson et al. Journal of Clinical Oncology profile →
  6. Phase 3 trial of everolimus for metastatic renal cell carcinoma
    2010 903 citations Robert J. Motzer, Stéphane Oudard et al. profile →
  7. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease
    2003 603 citations Hyung L. Kim, Robert A. Figlin et al. profile →
  8. Improved Prognostication of Renal Cell Carcinoma Using an Integrated Staging System
    2001 542 citations Robert A. Figlin, Arie S. Belldegrun et al. Journal of Clinical Oncology profile →
  9. Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience
    2005 535 citations Christopher G. Wood, Robert A. Figlin et al. Journal of Clinical Oncology profile →
  10. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
    2003 514 citations Bradley C. Leibovich, Robert A. Figlin et al. PubMed profile →
  11. Risk Group Assessment and Clinical Outcome Algorithm to Predict the Natural History of Patients With Surgically Resected Renal Cell Carcinoma
    2002 501 citations Robert A. Figlin, Arie S. Belldegrun et al. Journal of Clinical Oncology profile →
  12. Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
    2011 446 citations Brian I. Rini, Robert A. Figlin et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert A. Figlin United States 90 25.4k 22.0k 12.1k 12.1k 4.7k 470 38.0k
Bernard Escudier France 90 26.8k 1.1× 22.9k 1.0× 14.5k 1.2× 14.0k 1.2× 4.1k 0.9× 717 41.8k
Ronald M. Bukowski United States 77 19.9k 0.8× 17.7k 0.8× 13.4k 1.1× 10.3k 0.9× 3.2k 0.7× 459 34.0k
Brian I. Rini United States 94 25.8k 1.0× 19.7k 0.9× 15.6k 1.3× 12.9k 1.1× 4.1k 0.9× 769 38.4k
Stéphane Oudard France 73 27.5k 1.1× 16.5k 0.7× 13.8k 1.1× 12.0k 1.0× 3.4k 0.7× 618 38.8k
Toni K. Choueiri United States 93 24.9k 1.0× 15.1k 0.7× 18.1k 1.5× 10.6k 0.9× 9.6k 2.0× 1.2k 41.8k
Robert J. Motzer United States 106 39.4k 1.5× 30.6k 1.4× 19.5k 1.6× 17.7k 1.5× 12.6k 2.6× 932 58.6k
Walter M. Stadler United States 77 14.1k 0.6× 11.9k 0.5× 9.4k 0.8× 7.2k 0.6× 4.4k 0.9× 473 26.8k
Roy S. Herbst United States 102 26.5k 1.0× 17.0k 0.8× 31.9k 2.6× 9.2k 0.8× 2.6k 0.5× 583 50.9k
Elizabeth A. Eisenhauer Canada 61 12.7k 0.5× 12.0k 0.5× 15.2k 1.3× 7.3k 0.6× 4.1k 0.9× 213 41.9k
Yi‐Long Wu China 82 35.1k 1.4× 12.7k 0.6× 28.8k 2.4× 10.1k 0.8× 2.9k 0.6× 1.1k 46.0k

Countries citing papers authored by Robert A. Figlin

Since Specialization
Citations

This map shows the geographic impact of Robert A. Figlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert A. Figlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert A. Figlin more than expected).

Fields of papers citing papers by Robert A. Figlin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert A. Figlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert A. Figlin. The network helps show where Robert A. Figlin may publish in the future.

Co-authorship network of co-authors of Robert A. Figlin

This figure shows the co-authorship network connecting the top 25 collaborators of Robert A. Figlin. A scholar is included among the top collaborators of Robert A. Figlin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert A. Figlin. Robert A. Figlin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Choueiri, Toni K., Todd M. Bauer, Jaime R. Merchan, et al.. (2025). Updated results from the phase 2 LITESPARK-003 study of belzutifan plus cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology. 43(5_suppl). 549–549.
2.
Motzer, Robert J., Manuela Schmidinger, Masatoshi Eto, et al.. (2023). LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy. Future Oncology. 19(2). 113–121. 25 indexed citations
3.
Kim, Kyung, Edwin M. Posadas, Kevin S. Scher, et al.. (2023). System-wide approach on biosimilars adoption in oncology: Strategic plan on switching and cost savings.. Journal of Clinical Oncology. 41(16_suppl). 1600–1600. 1 indexed citations
4.
Figlin, Robert A., Nizar M. Tannir, Robert G. Uzzo, et al.. (2020). Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research. 26(10). 2327–2336. 53 indexed citations
5.
Vail, Eric, Jianbo Song, Jing Xu, et al.. (2020). Comparison of Large, Medium, and Small Solid Tumor Gene Panels for Detection of Clinically Actionable Mutations in Cancer. Targeted Oncology. 15(4). 523–530. 9 indexed citations
6.
Rini, Brian I., E. Jason Abel, Laurence Albigès, et al.. (2020). Summary from the Kidney Cancer Association’s Inaugural Think Thank: Coalition for a Cure. Clinical Genitourinary Cancer. 19(2). 167–175. 3 indexed citations
7.
Adashek, Jacob J., et al.. (2019). Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma. Clinical Genitourinary Cancer. 17(3). e454–e460. 13 indexed citations
8.
Courtney, Kevin D., Jeffrey R. Infante, Elaine T. Lam, et al.. (2017). Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology. 36(9). 867–874. 296 indexed citations
9.
Chen, Jie‐Fu, Yi‐Tsung Lu, Shirley Cheng, et al.. (2017). Circulating tumor cells in prostate cancer: beyond enumeration.. PubMed. 15(1). 63–73. 9 indexed citations
10.
Wang, Yanping, Tim Sparwasser, Robert A. Figlin, & Hyung L. Kim. (2014). Foxp3+ T Cells Inhibit Antitumor Immune Memory Modulated by mTOR Inhibition. Cancer Research. 74(8). 2217–2228. 30 indexed citations
11.
Motzer, Robert J., Thomas E. Hutson, Gary R. Hudes, et al.. (2014). Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. Cancer Chemotherapy and Pharmacology. 74(4). 739–750. 56 indexed citations
12.
Hong, Xin, Andreas Herrmann, Karen L. Reckamp, et al.. (2011). Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480. Cancer Research. 71(21). 6601–6610. 93 indexed citations
13.
Kujawski, Maciej, Chunyan Zhang, Andreas Herrmann, et al.. (2010). Targeting STAT3 in Adoptively Transferred T Cells Promotes Their In Vivo Expansion and Antitumor Effects. Cancer Research. 70(23). 9599–9610. 99 indexed citations
14.
Herrmann, Andreas, Marcin Kortylewski, Maciej Kujawski, et al.. (2010). Targeting Stat3 in the Myeloid Compartment Drastically Improves the In vivo Antitumor Functions of Adoptively Transferred T Cells. Cancer Research. 70(19). 7455–7464. 110 indexed citations
15.
Motzer, Robert J., Thomas E. Hutson, Piotr Tomczak, et al.. (2009). Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 27(22). 3584–3590. 1711 indexed citations breakdown →
16.
Hong, Xin, Chunyan Zhang, Andreas Herrmann, et al.. (2009). Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells. Cancer Research. 69(6). 2506–2513. 400 indexed citations
17.
Motzer, Robert J., M. Dror Michaelson, Bruce G. Redman, et al.. (2005). Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 24(1). 16–24. 1304 indexed citations breakdown →
18.
Riedl, Karen, Felicita Baratelli, Raj K. Batra, et al.. (2003). Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells.. Molecular Cancer. 2(1). 35–35. 30 indexed citations
19.
Belldegrun, Arie S., et al.. (2002). Renal and adrenal tumors : biology and management. Oxford University Press eBooks. 13 indexed citations
20.
Yang, Honghao, Michael H. Rosove, & Robert A. Figlin. (1999). Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: High-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. American Journal of Hematology. 62(4). 247–250. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bernard Escudier Breakdown of academic impact, for papers by Ronald M. Bukowski Breakdown of academic impact, for papers by Brian I. Rini Breakdown of academic impact, for papers by Stéphane Oudard Breakdown of academic impact, for papers by Toni K. Choueiri Breakdown of academic impact, for papers by Robert J. Motzer Breakdown of academic impact, for papers by Walter M. Stadler Breakdown of academic impact, for papers by Roy S. Herbst Breakdown of academic impact, for papers by Elizabeth A. Eisenhauer Breakdown of academic impact, for papers by Yi‐Long Wu
Rankless by CCL
2026